The FDA has issued a warning letter to Celltrion, maker of the infliximab biosimilar Inflectra. The company announced today that, on January 30, the company received a letter from the agency that “raises issues related to certain manufacturing process[es]” at its Incheon, Republic of Korea facility.
The FDA has issued a warning letter to Celltrion, maker of the infliximab biosimilar Inflectra. The company announced today that, on January 30, the company received a letter from the agency that “raises issues related to certain manufacturing process[es]” at its Incheon, Republic of Korea facility.
Celltrion’s statement added that the company is “making progress addressing these concerns,” and is committed to working with the FDA to address the outstanding issues. Celltrion will provide a full response to the FDA’s letter within the next 15 days.
The company’s statement did not enumerate the issues of concern to the FDA, but news of the letter follows the September 2017 release of an FDA Form 483, which, while heavily redacted, indicated that, between the fourth quarter of 2015 and the time of the form’s issuance, the FDA received 140 complaints about vial stoppers, and that Celltrion had not yet implemented adequate corrective and preventive measures to address the problem.
The form noted a variety of inspection observations, including failure to review unexplained discrepancies (including issues with vial stoppers and the release of drug batches that contained particulate matter), failure to establish and follow procedures to prevent microbiological contamination, a lack of an adequate validation of the sterilization process, deficient environmental monitoring, deficient cleaning and disinfecting, inappropriate equipment design, flawed data documentation and incomplete records, failure to demonstrate that the manufacturing process can reproducibly manufacture drugs meeting quality standards, and inappropriate systems controls.
In its February 1 statement, Celltrion indicated that that the warning letter does not negatively impact the company’s ability to continue to make and supply Inflectra from the facility in question. However, it did not address whether the issues impact its rituximab biosimilar, which is authorized for marketing in the European Union as Truxima, or its trastuzumab biosimilar, which received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in December 2017 and is awaiting final European Commission authorization.
Both the rituximab biosimilar and the trastuzumab biosimilar are currently under review by the FDA, with estimated regulatory action dates of February 2018 and March 2018, respectively. Notably, no Oncologic Drugs Advisory Committee meeting has been announced for either biosimilar.
Reuters reports that Celltrion’s shares fell by 5% on the news of the warning letter.
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.